Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

IBRX-042

Vaccine (Adenoviral vector) · Immune activation, directed at HPV-16 E6 oncoprotein and HPV-16 E7 oncoprotein · developed by ImmunityBio

Phase 1 Most advanced trial

IBRX Developer

1 Registered trials

What is IBRX-042?

IBRX-042 is an adenovirus type 5 vaccine encoding HPV-16 E6 and E7 oncoproteins. It stimulates cytotoxic T-lymphocyte responses against tumor cells expressing these viral antigens. The vaccine is studied in HPV-related carcinomas.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Vaccine (Adenoviral vector)
Targets: HPV-16 E6 oncoprotein (antigen), HPV-16 E7 oncoprotein (antigen)
Mechanism: Immune activation, directed at HPV-16 E6 oncoprotein and HPV-16 E7 oncoprotein
Pathways: cytotoxic T-lymphocyte response
Therapy area: Oncology
Developer: ImmunityBio, Inc. (IBRX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05976828	Phase 1	HPV-Related Carcinoma	Active not recruiting	IBRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HPV-Related Carcinoma

More from ImmunityBio

Nogapendekin Alfa Inbakicept FDA approved 5Fluorouracil Phase 2 AAHI-SC2 Phase 1/2 AAHI-SC3 Phase 1/2 Adenoviral Vector Ad5-CEA Vaccine Phase 1/2 agenT-797 Phase 3 Aldoxorubicin Phase 2 CD19 t-haNK Phase 2 ETBX-021 Phase 1/2 ETBX-051 Phase 1/2 ETBX-061 Phase 1/2 ETBX-071 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the IBRX page.

Follow IBRX, the company behind IBRX-042

See IBRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IBRX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z